632ac2fc-e387-461f-97e2-bc72b1c9ffe4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- PANCREAS_BETA_CELLS+0.190
- MYOGENESIS+0.170
- INFLAMMATORY_RESPONSE+0.160
- COAGULATION+0.140
- KRAS_SIGNALING_DN+0.140
- APICAL_JUNCTION+0.090
- KRAS_SIGNALING_UP+0.090
- COMPLEMENT+0.060
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.510
- MYC_TARGETS_V2-0.460
- ADIPOGENESIS-0.400
- FATTY_ACID_METABOLISM-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- E2F_TARGETS-0.390
- MTORC1_SIGNALING-0.390
- MYC_TARGETS_V1-0.390
- PEROXISOME-0.330
- PI3K_AKT_MTOR_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-MN-A4N4-01A-12R-A24X-07 | — | cohortA1 | 0.863 |
| 2 | C3N-00175 | — | cohortA1 | 0.841 |
| 3 | MNG974 | — | — | 0.830 |
| 4 | 7900174d-af00-444f-a5b2-226a45f7e76a | — | — | 0.802 |
| 5 | SRR9879291 | — | cohortMD2 | 0.801 |
| 6 | TCGA-55-8096-01A-11R-2241-07 | — | cohortA1 | 0.798 |
| 7 | SRR9879289 | — | cohortSQ1 | 0.796 |
| 8 | MNG145 | — | — | 0.795 |
| 9 | TCGA-FJ-A3Z7-01A-12R-A23N-07 | — | — | 0.791 |
| 10 | SRR15069598 | — | — | 0.791 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.060 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| HYPOXIA | 0.030 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.030 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |